Pemafibrate

AssetAlso K-808

Selective peroxisome proliferator-activated receptor alpha (SPPARM-alpha) agonist.

Stage: Phase 2
Modality: Small molecule
Target: Lipid and ceramide metabolism; 1
Indication: 1
Trial: 1
Developer

Indications

1

Primary biliary cholangitis
Phase 2, Completed, NCT06247735, clinicaltrials.gov, 8 Oct 2026

In the full profile

Targets and what it contains3
Owner and partners1
Trials1
Evidence for its targets4
Competitors9
Aging relevance1

Every asset’s record: target, stage, trials and the evidence behind it.

Updated 8 Oct 2026, 1 source